PUBLISHER: IMARC | PRODUCT CODE: 1390611
PUBLISHER: IMARC | PRODUCT CODE: 1390611
The global hormonal contraceptive market size reached US$ 17.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.19% during 2022-2028.
Hormonal contraceptives are formulations of progestin or a combination of estrogen and progesterone hormones. They act on the endocrine system to prevent ovulation and fertilization. As a result, they are used for preventing unwanted pregnancies and are also known to relieve period pain and often result in lighter periods. Hormonal contraceptives are considered one of the most effective methods, which can be taken before and after vaginal intercourse. They include birth control pills, vaginal rings, contraceptive skin patches, and hormone-releasing contraceptive coils. Hormonal contraceptives also affect the womb lining, making it hard for the fertilized eggs to be implanted.
The global hormonal contraceptive market is primarily driven by the increasing awareness among the masses regarding family planning. This has facilitated the need to prevent unintended pregnancies, especially among young couples. Furthermore, a significant rise in health issues associated with teenage pregnancies is promoting the use of contraceptives as they are easily accessible. Governments of different countries are also adopting various initiatives to support and improve access to these products by promoting affordable and high-quality healthcare services. Besides this, the advancements in the healthcare industry have resulted in the production of innovative products such as hormonal patches, implants, intrauterine devices, and drug-device combination products. These devices have fewer side effects and enhanced levels of efficiency in preventing pregnancy, which is favorably influencing the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hormonal contraceptive market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, hormone, age group and end user.
Oral Contraceptive Pills
Intrauterine Device (IUD)
Injectable Birth Control
Vaginal Rings
Others
Progestin-only Contraceptive
Combined Hormonal Contraceptive
15-24 Years
25-34 Years
35-44 Years
Above 44 Years
Hospitals and Clinics
Homecare
Ambulatory Surgical Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Afaxys Inc., Agile Therapeutics Inc., Allergan Inc. (AbbVie Inc.), Bayer AG, Cipla Limited, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Piramal Group and Teva Pharmaceutical Industries Ltd.